LEADER 03016nam 2200565 a 450 001 9910437830803321 005 20200520144314.0 010 $a1-283-84897-X 010 $a1-4614-4732-1 024 7 $a10.1007/978-1-4614-4732-0 035 $a(CKB)2670000000278640 035 $a(EBL)1030812 035 $a(OCoLC)820362341 035 $a(SSID)ssj0000789991 035 $a(PQKBManifestationID)11430979 035 $a(PQKBTitleCode)TC0000789991 035 $a(PQKBWorkID)10737083 035 $a(PQKB)10495643 035 $a(DE-He213)978-1-4614-4732-0 035 $a(MiAaPQ)EBC1030812 035 $a(PPN)168301059 035 $a(EXLCZ)992670000000278640 100 $a20120924d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCancer immunotherapy $eparadigms, practice and promise /$fTyler Curiel, editor 210 $aNew York $cSpringer$d2013 215 $a1 online resource (485 p.) 300 $aDescription based upon print version of record. 311 $a1-4614-4731-3 320 $aIncludes bibliographical references and index. 327 $apt. I. Overview -- pt. II. Passive strategies to boost antitumor immunity -- pt. III. Active strategies to boost antitumor immunity -- pt. IV. Additional strategies and considerations. 330 $aThis volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press. 606 $aCancer$xImmunological aspects 606 $aImmunotherapy 615 0$aCancer$xImmunological aspects. 615 0$aImmunotherapy. 676 $a616.99 676 $a616.994061 701 $aCuriel$b Tyler$01061617 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437830803321 996 $aCancer immunotherapy$92519370 997 $aUNINA